Cargando…
Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p
BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exos...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603694/ https://www.ncbi.nlm.nih.gov/pubmed/33129330 http://dx.doi.org/10.1186/s12951-020-00716-0 |
_version_ | 1783603980544245760 |
---|---|
author | Zhuang, Lei Xia, Wenzheng Chen, Didi Ye, Yijia Hu, Tingting Li, Shiting Hou, Meng |
author_facet | Zhuang, Lei Xia, Wenzheng Chen, Didi Ye, Yijia Hu, Tingting Li, Shiting Hou, Meng |
author_sort | Zhuang, Lei |
collection | PubMed |
description | BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosome(MIF)) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs). This study aimed to investigate the role of exosome(MIF) in the treatment of DIC. RESULTS: Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome(MIF)). Regulatory lncRNAs activated by MIF pretreatment were explored using genomics approaches. Fluorescence-labeled exosomes were tracked in vitro by fluorescence imaging. In vivo and in vitro, miR-221-3p mimic transfection enforced miR-221-3p overexpression, and senescence-associated β-galactosidase assay was applied to test cellular senescence. Exosomal delivering LncRNA-NEAT1 induced therapeutic effect in vivo was confirmed by echocardiography. It demonstrated that exosomes(MIF) recovered the cardiac function and exerted the anti-senescent effect through LncRNA–NEAT1 transfer against Dox. TargetScan and luciferase assay showed that miR-221-3p targeted the Sirt2 3′-untranslated region. Silencing LncRNA–NEAT1 in MSCs, miR-221-3p overexpression or Sirt2 silencing in cardiomyocytes decreased the exosome(MIF)-induced anti-senescent effect against Dox. CONCLUSIONS: The results indicated exosome(MIF) serving as a promising anti-senescent effector against Dox-induced cardiotoxicity through LncRNA–NEAT1 transfer, thus inhibiting miR-221-3p and leading to Sirt2 activation. The study proposed that exosome(MIF) might have the potential to serve as a cardioprotective therapeutic agent during cancer chemotherapy. [Image: see text] |
format | Online Article Text |
id | pubmed-7603694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-76036942020-11-02 Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p Zhuang, Lei Xia, Wenzheng Chen, Didi Ye, Yijia Hu, Tingting Li, Shiting Hou, Meng J Nanobiotechnology Research BACKGROUND: The chemotherapy drug doxorubicin (Dox) is widely used for treating a variety of cancers. However, its high cardiotoxicity hampered its clinical use. Exosomes derived from stem cells showed a therapeutic effect against Dox-induced cardiomyopathy (DIC). Previous studies reported that exosomes derived from mesenchymal stem cells (MSCs) pretreated with macrophage migration inhibitory factor (MIF) (exosome(MIF)) showed a cardioprotective effect through modulating long noncoding RNAs/microRNAs (lncRNAs/miRs). This study aimed to investigate the role of exosome(MIF) in the treatment of DIC. RESULTS: Exosomes were isolated from control MSCs (exosome) and MIF-pretreated MSCs (exosome(MIF)). Regulatory lncRNAs activated by MIF pretreatment were explored using genomics approaches. Fluorescence-labeled exosomes were tracked in vitro by fluorescence imaging. In vivo and in vitro, miR-221-3p mimic transfection enforced miR-221-3p overexpression, and senescence-associated β-galactosidase assay was applied to test cellular senescence. Exosomal delivering LncRNA-NEAT1 induced therapeutic effect in vivo was confirmed by echocardiography. It demonstrated that exosomes(MIF) recovered the cardiac function and exerted the anti-senescent effect through LncRNA–NEAT1 transfer against Dox. TargetScan and luciferase assay showed that miR-221-3p targeted the Sirt2 3′-untranslated region. Silencing LncRNA–NEAT1 in MSCs, miR-221-3p overexpression or Sirt2 silencing in cardiomyocytes decreased the exosome(MIF)-induced anti-senescent effect against Dox. CONCLUSIONS: The results indicated exosome(MIF) serving as a promising anti-senescent effector against Dox-induced cardiotoxicity through LncRNA–NEAT1 transfer, thus inhibiting miR-221-3p and leading to Sirt2 activation. The study proposed that exosome(MIF) might have the potential to serve as a cardioprotective therapeutic agent during cancer chemotherapy. [Image: see text] BioMed Central 2020-10-31 /pmc/articles/PMC7603694/ /pubmed/33129330 http://dx.doi.org/10.1186/s12951-020-00716-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Zhuang, Lei Xia, Wenzheng Chen, Didi Ye, Yijia Hu, Tingting Li, Shiting Hou, Meng Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title | Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title_full | Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title_fullStr | Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title_full_unstemmed | Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title_short | Exosomal LncRNA–NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p |
title_sort | exosomal lncrna–neat1 derived from mif-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging mir-221-3p |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603694/ https://www.ncbi.nlm.nih.gov/pubmed/33129330 http://dx.doi.org/10.1186/s12951-020-00716-0 |
work_keys_str_mv | AT zhuanglei exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT xiawenzheng exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT chendidi exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT yeyijia exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT hutingting exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT lishiting exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p AT houmeng exosomallncrnaneat1derivedfrommiftreatedmesenchymalstemcellsprotectedagainstdoxorubicininducedcardiacsenescencethroughspongingmir2213p |